AIM-listed specialist drug discovery and development company ImmuPharma has been out of favour with investors recently and the shares are languishing at close to all-time lows.  It may be that investors have found better short-term opportunities elsewhere in recent months given market conditions as, contrary to what the charts may suggest, the company has done nothing to disappoint.  There was a placing in September at 11p per share and the chance to buy in now at a discount to that level looks very tempting.

ImmuPharma is a specialty biopharmaceutical company focused on the discovery and development of peptide-based therapeutics.  It has operations in the UK, France and Switzerland, with a formal research collaboration with the Centre National de la Recherche Scientifique in France.  A partnership-based business model means that there is a small core of full time staff and a low cost base.

The company has a portfolio which includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer.  The lead program, Lupuzor, is a first-in-class autophagy immunomodulator which is in Phase 3 for the treatment of lupus.  Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.  In November 2019 ImmuPharma and Avion Pharmaceuticals signed an exclusive licence and development agreement and trademark agreement for Lupuzor, to fund a new international Phase 3 trial for Lupuzor and commercialise in the US.

The last piece of meaningful news from the company was on 9 February when an update on the new optimised international Phase 3 trial of Lupuzor in systemic lupus erythematosus, which is a potentially life-threatening auto-immune disease, was released.  Lupuzor continues to progress towards the commencement of the international Phase 3 trial with Avion Pharmaceuticals.  The Phase 3 study remains on schedule for the second half of 2021.

It is surprising that the shares are at such a low level by historical standards and the company will surely attract some interest in the coming months.  Final results are due out in the near future although, given the company’s stage of development, these are likely to be fairly pedestrian.  Nevertheless, some attention may be drawn to the shares at what looks to be a bargain price.  We rate ImmuPharma as a SPECULATIVE BUY.


RECENT TIPS – The highs and the lows


For a flavour of our performance recently, we list below some of our recommendations that we have made in the last week or so: 


HSS Hire – 19.6p at close on 6 April (tipped at 16.85p on 31 March) – gain of 16%.  

*Investors realise the stock is too cheap


Gfinity – 4.59p at close on 6 April (tipped at 3.8p on 29 March) – gain of 21%.  

*Further consideration of interim results 


Logistics Development Group – 13.35p at close on 6 April (tipped at 14.875p on 30 March) – a loss of 10%. 

*Share price fall due to lack of positive news on company’s future plans  


To read about some of our other recent top performing share tips, head to 

Brought to you by City Confidential


All research on the website has been prepared and issued by cityconfidential for publication in the United Kingdom. All information used in the publication of this research, has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness. Opinions contained in this research represent those of the research department of brokerlink at the time of publication. The research on this website is intended for professional advisors in the United Kingdom for use in their role as advisors. It is not intended for private individuals or investors. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Research is provided for information purposes only and should not be construed as an offer or solicitation for investment. This research is non-objective. cityconfidential does not conduct investment business and as such does not hold any positions in the securities mentioned in this report. However its directors, officers, employees and contractors may have a position in any or related securities. cityconfidential may perform services or solicit business from any of the companies mentioned in this research. The value of securities mentioned can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this research. Past performance is not necessarily a guide to future performance.

cityconfidential is owned by Independent Financial Publications, which is authorised and regulated by the Financial Services Authority.

No Comments

Post a Comment